Literature DB >> 6199137

Neuropeptides contained in peripheral cardiovascular nerves.

J B Furness, M Costa, R E Papka, N G Della, R Murphy.   

Abstract

The neuropeptides, substance P, vasoactive intestinal peptide (VIP), neuropeptide Y and enkephalin have been found in nerves associated with the heart and blood vessels of a range of mammals, including man. There is also evidence for some cardiovascular nerves with gastrin releasing peptide and neurotensin immunoreactivity. Substance P is in sensory nerves with a widespread distribution to the heart and all vascular beds. In general, large arteries have the densest innervation and the density of nerves decreases as arterial size decreases. In adult guinea-pigs, an adequate treatment with capsaicin causes the degeneration of almost all cardiovascular substance P nerves. Using capsaicin as a tool it has been shown that the substance P containing sensory nerves are not essential for baroreceptor reflexes. VIP nerves also have a widespread distribution, being particularly prominent in the cerebral arteries, uterine arteries and arteries of erectile and secretory tissues. Neuropeptide Y is located in the same cardiovascular nerves as noradrenaline. It is depleted from the nerves by reserpine or 6-hydroxydopamine. Enkephalin nerves have been reported with small arteries in only a few vascular beds.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6199137     DOI: 10.3109/10641968409062553

Source DB:  PubMed          Journal:  Clin Exp Hypertens A        ISSN: 0730-0077


  11 in total

1.  Effects of sympathetic activity and galanin on cardiac vagal action in anaesthetized cats.

Authors:  L G Ulman; E K Potter; D I McCloskey
Journal:  J Physiol       Date:  1992-03       Impact factor: 5.182

2.  Sympathetic-parasympathetic interactions at the heart, possibly involving neuropeptide Y, in anaesthetized dogs.

Authors:  M L Revington; D I McCloskey
Journal:  J Physiol       Date:  1990-09       Impact factor: 5.182

3.  The role of magnesium deficiency in cardiovascular and intestinal inflammation.

Authors:  William B Weglicki; Iu Tong Mak; Joanna J Chmielinska; Maria Isabel Tejero-Taldo; Andrei M Komarov; Jay H Kramer
Journal:  Magnes Res       Date:  2010-10-25       Impact factor: 1.115

4.  The peptidergic innervation of the developing mesenteric vascular bed in the rat.

Authors:  T M Scott; J Robinson; J Foote
Journal:  J Anat       Date:  1989-02       Impact factor: 2.610

5.  Substance P induces adverse myocardial remodelling via a mechanism involving cardiac mast cells.

Authors:  Giselle C Meléndez; Jianping Li; Brittany A Law; Joseph S Janicki; Scott C Supowit; Scott P Levick
Journal:  Cardiovasc Res       Date:  2011-09-09       Impact factor: 10.787

Review 6.  Neurogenic inflammation and cardiac dysfunction due to hypomagnesemia.

Authors:  Jay H Kramer; Christopher Spurney; Micaela Iantorno; Constantine Tziros; I-Tong Mak; M Isabel Tejero-Taldo; Joanna J Chmielinska; Andrei M Komarov; William B Weglicki
Journal:  Am J Med Sci       Date:  2009-07       Impact factor: 2.378

7.  Lack of circadian rhythm of plasma concentrations of vasoactive intestinal peptide in patients with orthotopic heart transplants.

Authors:  P Cugini; P Lucia; G Scibilia; L Di Palma; A R Cioli; A Cianetti; L Gasbarrone; R Canova; B Marino
Journal:  Br Heart J       Date:  1993-10

8.  Neutral endopeptidase inhibition enhances substance P mediated inflammation due to hypomagnesemia.

Authors:  William B Weglicki; Joanna J Chmielinska; Isabel Tejero-Taldo; Jay H Kramer; Christopher F Spurney; Kandan Viswalingham; Bao Lu; I Tong Mak
Journal:  Magnes Res       Date:  2009-09       Impact factor: 1.115

9.  Substance P increases sympathetic activity during combined angiotensin-converting enzyme and dipeptidyl peptidase-4 inhibition.

Authors:  Jessica K Devin; Mias Pretorius; Hui Nian; Chang Yu; Frederic T Billings; Nancy J Brown
Journal:  Hypertension       Date:  2014-02-10       Impact factor: 10.190

10.  Sympathetic nervous system modulation of inflammation and remodeling in the hypertensive heart.

Authors:  Scott P Levick; David B Murray; Joseph S Janicki; Gregory L Brower
Journal:  Hypertension       Date:  2010-01-04       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.